

Westenbrink, Bd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3047869/publications.pdf>

Version: 2024-02-01

81
papers

3,496
citations

218677

26
h-index

144013

57
g-index

85
all docs

85
docs citations

85
times ranked

4201
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. <i>European Journal of Heart Failure</i> , 2019, 21, 862-873.	7.1	236
2	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018, 138, 678-691.	1.6	229
3	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <i>European Heart Journal</i> , 2007, 28, 2018-2027.	2.2	210
4	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	2.8	199
5	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. <i>Heart</i> , 2010, 96, 1297-1302.	2.9	179
6	A Single Bolus of a Long-acting Erythropoietin Analogue Darbeoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 135-141.	2.6	176
7	Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1559-1566.	7.1	173
8	Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. <i>European Heart Journal</i> , 2006, 28, 166-171.	2.2	134
9	Levels of Hematopoiesis Inhibitor <i>N¹-Acetyl-Seryl-Aspartyl-Lysyl-Proline</i> Partially Explain the Occurrence of Anemia in Heart Failure. <i>Circulation</i> , 2005, 112, 1743-1747.	1.6	120
10	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1660-1669.	2.8	111
11	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2378-2388.	2.8	108
12	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	3.8	108
13	Differential associations between renal function and modifiable risk factors in patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2009, 98, 121-129.	3.3	101
14	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007684.	3.9	87
15	Bone marrow dysfunction in chronic heart failure patients. <i>European Journal of Heart Failure</i> , 2010, 12, 676-684.	7.1	86
16	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <i>European Journal of Heart Failure</i> , 2008, 10, 22-29.	7.1	72
17	Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. <i>Cardiovascular Research</i> , 2010, 87, 30-39.	3.8	72
18	CaMKII γ subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF- κ B and TNF- α . <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 103, 48-55.	1.9	62

#	ARTICLE	IF	CITATIONS
19	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	2.7	54
20	Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the REâ€LY trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 699-707.	3.8	53
21	Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial. <i>Heart</i> , 2011, 97, 1590-1596.	2.9	52
22	Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 265-274.	2.6	51
23	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. <i>Vaccine Journal</i> , 2005, 12, 125-129.	3.1	47
24	Mitochondrial Reprogramming Induced by CaMKII β Mediates Hypertrophy Decompensation. <i>Circulation Research</i> , 2015, 116, e28-39.	4.5	47
25	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009238.	3.9	40
26	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. <i>Cardiovascular Diabetology</i> , 2020, 19, 5.	6.8	29
27	Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia. <i>Cardiovascular Research</i> , 2013, 98, 37-46.	3.8	26
28	The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 889-903.	3.4	26
29	Ketone bodies for the failing heart: fuels that can fix the engine?. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 814-826.	7.1	26
30	Anemia in chronic heart failure: etiology and treatment options. <i>Current Opinion in Cardiology</i> , 2008, 23, 141-147.	1.8	25
31	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <sc>VIPâ€HF</sc> study. <i>European Journal of Heart Failure</i> , 2020, 22, 1923-1929.	7.1	25
32	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 1.	3.5	25
33	Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. <i>Cardiovascular Research</i> , 2016, 111, 217-226.	3.8	24
34	Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with midâ€range and preserved ejection fraction. <i>Clinical Cardiology</i> , 2021, 44, 987-993.	1.8	22
35	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22
36	Association of Circulating Ketone Bodiesâ€With Functional Outcomes Afterâ€ST-Segment Elevation Myocardialâ€Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1421-1432.	2.8	21

#	ARTICLE	IF	CITATIONS
37	Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 348-353.	7.1	19
38	Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C155-C163.	4.6	19
39	Erythropoietin in cardiac disease: New features of an old drug. <i>European Journal of Pharmacology</i> , 2008, 585, 270-277.	3.5	18
40	AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes. <i>PLoS ONE</i> , 2013, 8, e80815.	2.5	18
41	Short-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	18
42	Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2301-2302.	2.8	17
43	AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway. <i>International Journal of Molecular Sciences</i> , 2013, 14, 21378-21393.	4.1	17
44	Temporal patterns of macrophage- and neutrophil-related markers are associated with clinical outcome in heart failure patients. <i>ESC Heart Failure</i> , 2020, 7, 1190-1200.	3.1	17
45	Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy. <i>Biological Research</i> , 2021, 54, 3.	3.4	17
46	Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier. <i>Journal of the American Heart Association</i> , 2020, 9, e018641.	3.7	16
47	Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?. <i>European Journal of Heart Failure</i> , 2022, 24, 287-298.	7.1	16
48	Can Critically Short Telomeres Cause Functional Exhaustion of Progenitor Cells in Postinfarction Heart Failure?. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1911-1912.	2.8	14
49	Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. <i>International Journal of Cardiology</i> , 2013, 169, 385-393.	1.7	14
50	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. <i>American Heart Journal</i> , 2009, 157, 91-96.	2.7	13
51	Erythropoietin and heart failure: the end of a promise?. <i>European Journal of Heart Failure</i> , 2013, 15, 479-481.	7.1	13
52	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.	3.9	13
53	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2458-2466.	3.1	13
54	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11906.	4.1	13

#	ARTICLE	IF	CITATIONS
55	Î²-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 277-285.	2.6	12
56	Heart failure highlights in 2012â€“2013. <i>European Journal of Heart Failure</i> , 2014, 16, 122-132.	7.1	11
57	Effects of Sodiumâ€“Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 311-321.	2.6	10
58	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. <i>Pflügers Archiv European Journal of Physiology</i> , 2021, 473, 1301-1313.	2.8	10
59	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. <i>Current Heart Failure Reports</i> , 2007, 4, 127-133.	3.3	9
60	Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium. <i>Netherlands Heart Journal</i> , 2010, 18, 236-242.	0.8	9
61	Heart failure specialization in Europe. <i>European Journal of Heart Failure</i> , 2016, 18, 347-349.	7.1	9
62	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca ²⁺ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIÎ³. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4427.	4.1	9
63	The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction. <i>Heart and Vessels</i> , 2022, 37, 273-281.	1.2	8
64	Chagas, a cardiomyopathy emerging from obscurity. <i>European Journal of Heart Failure</i> , 2015, 17, 355-357.	7.1	5
65	Selecting heart failure patients for metabolic interventions. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 141-152.	3.1	5
66	Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. <i>Netherlands Heart Journal</i> , 2021, 29, 383-393.	0.8	5
67	Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens. <i>European Journal of Heart Failure</i> , 2020, 22, 455-457.	7.1	4
68	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 35, 953-963.	2.6	4
69	Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial. <i>American Heart Journal</i> , 2022, 246, 166-177.	2.7	4
70	Heart failure highlights in 2011. <i>European Journal of Heart Failure</i> , 2012, 14, 1090-1096.	7.1	3
71	Imaging the cardiac diet. <i>European Journal of Heart Failure</i> , 2013, 15, 123-124.	7.1	3
72	<sc>CaMKII</sc> confirms its promise in ischaemic heart disease. <i>European Journal of Heart Failure</i> , 2014, 16, 1268-1269.	7.1	3

#	ARTICLE	IF	CITATIONS
73	Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor- κ B to the rescue?. Cardiovascular Research, 2020, 116, 1092-1094.	3.8	3
74	Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clinical Research in Cardiology, 2014, 103, 467-476.	3.3	2
75	<sc>BNP</sc> in heart failure: even leucocytes cannot escape its influence. European Journal of Heart Failure, 2015, 17, 536-538.	7.1	2
76	What You Did Not Know About Cardiac Ca ²⁺ Handling. Circulation, 2021, 143, 466-469.	1.6	2
77	Haemodilution is a mechanism of anaemia in patients with heart failure: reply. European Journal of Heart Failure, 2013, 15, 1074-1075.	7.1	0
78	Cardiac resynchronization therapy in mild heart failure should be reserved for true dyssynchronopathy. European Journal of Heart Failure, 2015, 17, 239-241.	7.1	0
79	CardioPulse Articles The Heart Failure Association of the European Society of Cardiology: Second decade of success Graduation of First Postgraduate Course in Heart Failure The Postgraduate Course in Heart Failure The second Postgraduate Course in Heart Failure: 2016-2017 Leaders in cardiovascular medicine today Dr Marc Pfeffer PhD MD Settling scores with a failing heart Pocket-sized ultrasound for nurses in heart failure? PARADIGM-HF trial most favoured at European Society of Cardiology Congress London . European Heart Journal, 2016, 37, 425-436.	2.2	0
80	Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy?. European Journal of Radiology, 2020, 126, 108971.	2.6	0
81	Reply to "Exercise intolerance in heart failure: beyond mitochondrial dysfunction". Letter regarding the article "Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?". European Journal of Heart Failure, 2022, 24, 910-911.	7.1	0